+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2015

  • ID: 3275751
  • Report
  • May 2015
  • 43 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Beech Tree Labs, Inc.
  • Mymetics Corporation
  • NanoViricides, Inc.
  • Onxeo SA
  • Spider Biotech
  • MORE
Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2015

Summary

The‘Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2015’, provides an overview of the Herpes Labialis (Oral Herpes)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Herpes Labialis (Oral Herpes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Labialis (Oral Herpes) and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Herpes Labialis (Oral Herpes)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Herpes Labialis (Oral Herpes) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Herpes Labialis (Oral Herpes) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Herpes Labialis (Oral Herpes) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Herpes Labialis (Oral Herpes)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • Beech Tree Labs, Inc.
  • Mymetics Corporation
  • NanoViricides, Inc.
  • Onxeo SA
  • Spider Biotech
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Herpes Labialis (Oral Herpes) Overview

Therapeutics Development

Pipeline Products for Herpes Labialis (Oral Herpes) - Overview

Pipeline Products for Herpes Labialis (Oral Herpes) - Comparative Analysis

Herpes Labialis (Oral Herpes) - Therapeutics under Development by Companies

Herpes Labialis (Oral Herpes) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Herpes Labialis (Oral Herpes) - Products under Development by Companies

Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development

Beech Tree Labs, Inc.

Foamix Pharmaceuticals Ltd.

Mymetics Corporation

NanoViricides, Inc.

Onxeo SA

Spider Biotech

Herpes Labialis (Oral Herpes) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

acyclovir - Drug Profile

Product Description

Mechanism of Action

R&D Progress

acyclovir - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Aspidasept - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BTL-TMLHSV - Drug Profile

Product Description

Mechanism of Action

R&D Progress

HerpeCide-I - Drug Profile

Product Description

Mechanism of Action

R&D Progress

herpes simplex virus [type 1, 2] vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SB-105A10 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Herpes Labialis (Oral Herpes) - Recent Pipeline Updates

Herpes Labialis (Oral Herpes) - Dormant Projects

Herpes Labialis (Oral Herpes) - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Herpes Labialis (Oral Herpes), H1 2015

Number of Products under Development for Herpes Labialis (Oral Herpes) - Comparative Analysis, H1 2015

Number of Products under Development by Companies, H1 2015

Comparative Analysis by Late Stage Development, H1 2015

Comparative Analysis by Clinical Stage Development, H1 2015

Comparative Analysis by Early Stage Development, H1 2015

Products under Development by Companies, H1 2015

Herpes Labialis (Oral Herpes) - Pipeline by Beech Tree Labs, Inc., H1 2015

Herpes Labialis (Oral Herpes) - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015

Herpes Labialis (Oral Herpes) - Pipeline by Mymetics Corporation, H1 2015

Herpes Labialis (Oral Herpes) - Pipeline by NanoViricides, Inc., H1 2015

Herpes Labialis (Oral Herpes) - Pipeline by Onxeo SA, H1 2015

Herpes Labialis (Oral Herpes) - Pipeline by Spider Biotech, H1 2015

Assessment by Monotherapy Products, H1 2015

Number of Products by Stage and Target, H1 2015

Number of Products by Stage and Mechanism of Action, H1 2015

Number of Products by Stage and Route of Administration, H1 2015

Number of Products by Stage and Molecule Type, H1 2015

Herpes Labialis (Oral Herpes) Therapeutics - Recent Pipeline Updates, H1 2015

Herpes Labialis (Oral Herpes) - Dormant Projects, H1 2015

Herpes Labialis (Oral Herpes) - Discontinued Products, H1 2015

List of Figures:

Number of Products under Development for Herpes Labialis (Oral Herpes), H1 2015

Number of Products under Development for Herpes Labialis (Oral Herpes) - Comparative Analysis, H1 2015

Number of Products under Development by Companies, H1 2015

Comparative Analysis by Early Stage Products, H1 2015

Assessment by Monotherapy Products, H1 2015

Number of Products by Top 10 Targets, H1 2015

Number of Products by Stage and Top 10 Targets, H1 2015

Number of Products by Top 10 Mechanism of Actions, H1 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015

Number of Products by Top 10 Routes of Administration, H1 2015

Number of Products by Stage and Top 10 Routes of Administration, H1 2015

Number of Products by Top 10 Molecule Types, H1 2015

Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
4 of 5
- Beech Tree Labs, Inc.
- Foamix Pharmaceuticals Ltd.
- Mymetics Corporation
- NanoViricides, Inc.
- Onxeo SA
- Spider Biotech
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll